Report

QuickView: New tool for a common problem

TearLab is commercialising an FDA-approved point-of-care (PoC) device to measure tear osmolarity in dry eye disease (DED) patients. DED symptoms account for one-third of all eye care visits. TearLab has shown revenue growth in the past two years, but continues to post losses due to slow product adoption. A Clinical Laboratory Improvement Amendments (CLIA) waiver, favourable economics and utility for eye doctors, together with a large potential market, point the way to TearLab reaching profitability.
Underlying
TearLab

TearLab is an in-vitro diagnostic company. The company has commercialized a tear testing platform, the TearLab

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch